The recent BioPharm Int. ebook on “Manufacturing and Facilities 2022” covers strategies and technologies used to address limited production capacities for biopharmaceutical. Our contributing article on our intensified, continuous bioprocess platform used at J.POD, our advanced cGMP biomanufacturing facility in Redmond, WA, describes the ongoing shift from fed-batch to continuous manufacturing and its advantages.
The benefits of our industry-leading intensified, continuous bioprocess platform are clear: enhanced productivity, better product quality, and greater cost efficiency.
Read the full article recently published in the BioPharm Int. ebook Nov 2022.